May 30, 2025
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
Oct 16, 2024
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
Apr 10, 2024
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
Jan 22, 2021
BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter
Jan 14, 2020
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe
Feb 04, 2019
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Dec 11, 2018
BioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration
Nov 01, 2018
BioLineRx to Report Third Quarter 2018 Results on November 8, 2018
May 22, 2018
BioLineRx Reports First Quarter 2018 Financial Results
Jan 17, 2018
BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer
Dec 05, 2017
BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY
Nov 21, 2017
BioLineRx Reports Third Quarter 2017 Financial Results
Sep 07, 2017
BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
Aug 08, 2017
BioLineRx Reports Second Quarter 2017 Financial Results
Aug 02, 2017
BioLineRx to Report Second Quarter 2017 Results on August 8, 2017